Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC-SA 4.0
ID Serval
serval:BIB_99272140464E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
Périodique
healthbook TIMES Oncology Hematology - Edition 3 / 2022
ISSN
2673-2106
2673-2092
2673-2092
Statut éditorial
Publié
Date de publication
31/10/2022
Peer-reviewed
Oui
Numéro
13
Langue
anglais
Résumé
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy continues to challenge standard
treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR
T-cell therapies are forging a path towards improving patient outcomes and health-related quality of life (HRQoL) in difficultto-
treat relapsed/refractory (R/R) blood cancers such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM),
mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). Here the latest data on commercially available
CAR T-cell therapies are summarized and discussed.
treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR
T-cell therapies are forging a path towards improving patient outcomes and health-related quality of life (HRQoL) in difficultto-
treat relapsed/refractory (R/R) blood cancers such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM),
mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). Here the latest data on commercially available
CAR T-cell therapies are summarized and discussed.
Mots-clé
Oncology, Hematology
Open Access
Oui
Création de la notice
17/08/2023 12:17
Dernière modification de la notice
18/08/2023 6:13
Données d'usage
